Company registration number 05942532 (England and Wales)
SQUARE EYECARE LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
PAGES FOR FILING WITH REGISTRAR
SQUARE EYECARE LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 7
SQUARE EYECARE LIMITED
BALANCE SHEET
AS AT
30 SEPTEMBER 2024
30 September 2024
- 1 -
2024
2023
Notes
£
£
£
£
Fixed assets
Tangible assets
4
132,982
176,395
Investments
5
755,554
516,709
888,536
693,104
Current assets
Stocks
32,450
32,500
Debtors
8
988,298
974,181
Cash at bank and in hand
796,238
605,890
1,816,986
1,612,571
Creditors: amounts falling due within one year
9
(273,979)
(251,585)
Net current assets
1,543,007
1,360,986
Total assets less current liabilities
2,431,543
2,054,090
Provisions for liabilities
(51,300)
(40,812)
Net assets
2,380,243
2,013,278
Capital and reserves
Called up share capital
10
2,100
2,100
Profit and loss reserves
2,378,143
2,011,178
Total equity
2,380,243
2,013,278

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 30 September 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and signed by the director and authorised for issue on 3 December 2024
Mr B Gallagher
Director
Company Registration No. 05942532
SQUARE EYECARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 2 -
1
Accounting policies
Company information

Square Eyecare Limited is a private company limited by shares incorporated in England and Wales. The registered office is 59-61 High Street, Southend-On-Sea, Essex, SS1 1HZ.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover represents amounts receivable for goods and services provided in the normal course of business, net of trade discounts, VAT and other sales-related taxes.

Turnover is recognised as earned when, and to the extent that, the company obtains the right to consideration in the exchange for goods and services provided.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from the provision of optometry services is recognised when the service is provided.

1.3
Intangible fixed assets other than goodwill

Intangible assets relate to a franchise fee paid and measured at cost less accumulated amortisation.

Amortisation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Intagible assets
5 years
1.4
Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Professional equipment
33% on cost and 8 years straight line
Fixtures, fittings & equipment
33% on cost
Computer equipment
33% on cost
SQUARE EYECARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
1
Accounting policies
(Continued)
- 3 -
1.5
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

 

Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account in other administrative expenses.

1.8
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

SQUARE EYECARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
1
Accounting policies
(Continued)
- 4 -
Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.9
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

1.10
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.11
Leases

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
23
27
3
Intangible fixed assets
Franchise
£
Cost
At 1 October 2023 and 30 September 2024
171,000
Amortisation and impairment
At 1 October 2023 and 30 September 2024
171,000
Carrying amount
At 30 September 2024
-
0
At 30 September 2023
-
0
SQUARE EYECARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 5 -
4
Tangible fixed assets
Professional equipment
Fixtures, fittings & equipment
Computer equipment
Total
£
£
£
£
Cost
At 1 October 2023
194,771
312,068
56,384
563,223
Additions
427
353
1,874
2,654
At 30 September 2024
195,198
312,421
58,258
565,877
Depreciation and impairment
At 1 October 2023
189,441
165,353
32,034
386,828
Depreciation charged in the year
5,058
29,955
11,054
46,067
At 30 September 2024
194,499
195,308
43,088
432,895
Carrying amount
At 30 September 2024
699
117,113
15,170
132,982
At 30 September 2023
5,330
146,715
24,350
176,395
5
Fixed asset investments
2024
2023
£
£
Other investments other than loans
755,554
516,709
Movements in fixed asset investments
Investments
£
Cost or valuation
At 1 October 2023
516,709
Additions
155,850
Valuation changes
82,995
At 30 September 2024
755,554
Carrying amount
At 30 September 2024
755,554
At 30 September 2023
516,709
SQUARE EYECARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
(Continued)
- 6 -
6
Subsidiaries

Details of the company's subsidiaries at 30 September 2024 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
S&B Eyecare Limited
19 The Grove Centre, Essex, CM8 2YT
Ordinary
60.00
7
Associates

Details of the company's associates at 30 September 2024 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Dan 1 Optics Limited
C/O Rsm, Brian Johnson Way, Preston, PR2 5PE
Ordinary
30.00
8
Debtors
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
36,278
38,356
Other debtors
952,020
935,825
988,298
974,181
9
Creditors: amounts falling due within one year
2024
2023
£
£
Bank loans
-
0
7,143
Trade creditors
149,247
126,666
Taxation and social security
106,482
111,174
Other creditors
18,250
6,602
273,979
251,585

Included in bank loans above is £nil (2023 - £7,143) secured by a guarantee from the director.

SQUARE EYECARE LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 SEPTEMBER 2024
- 7 -
10
Called up share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary of £1 each
100
100
100
100
Class A of £1 each
2,000
2,000
2,000
2,000
2,100
2,100
2,100
2,100

The company has 200,000 Class A shares in issue. As at the year end date 2,000 shares were called up and fully paid at £1 per share.

11
Related party transactions

During the year, the company loaned money to Rayleigh Eyecare Limited. At the year end, the amount owed from Rayleigh Eyecare Limited was £12,242 (2023: £5,327) this amount is included in debtors: amounts falling due within one year. A company with a common director.

 

During the year, the company loaned money to Rufiorka Limited. At the year end, the amount owed from Rufiorka Limited was £607,660 (2023: £608,603) this amount is included in debtors: amounts falling due within one year. A company with a common director.

2024-09-302023-10-01falsefalsefalse03 December 2024CCH SoftwareCCH Accounts Production 2024.310No description of principal activityMr B GallagherMr B Gallagher059425322023-10-012024-09-30059425322024-09-30059425322023-09-3005942532core:PlantMachinery2024-09-3005942532core:FurnitureFittings2024-09-3005942532core:ComputerEquipment2024-09-3005942532core:PlantMachinery2023-09-3005942532core:FurnitureFittings2023-09-3005942532core:ComputerEquipment2023-09-3005942532core:CurrentFinancialInstrumentscore:WithinOneYear2024-09-3005942532core:CurrentFinancialInstrumentscore:WithinOneYear2023-09-3005942532core:CurrentFinancialInstruments2024-09-3005942532core:CurrentFinancialInstruments2023-09-3005942532core:ShareCapital2024-09-3005942532core:ShareCapital2023-09-3005942532core:RetainedEarningsAccumulatedLosses2024-09-3005942532core:RetainedEarningsAccumulatedLosses2023-09-3005942532core:ShareCapitalOrdinaryShares2024-09-3005942532core:ShareCapitalOrdinaryShares2023-09-3005942532bus:CompanySecretaryDirector12023-10-012024-09-3005942532core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3005942532core:PatentsTrademarksLicencesConcessionsSimilar2023-10-012024-09-3005942532core:PlantMachinery2023-10-012024-09-3005942532core:FurnitureFittings2023-10-012024-09-3005942532core:ComputerEquipment2023-10-012024-09-30059425322022-10-012023-09-3005942532core:IntangibleAssetsOtherThanGoodwill2023-09-3005942532core:IntangibleAssetsOtherThanGoodwill2024-09-3005942532core:IntangibleAssetsOtherThanGoodwill2023-09-3005942532core:PlantMachinery2023-09-3005942532core:FurnitureFittings2023-09-3005942532core:ComputerEquipment2023-09-30059425322023-09-300594253212023-10-012024-09-300594253222023-10-012024-09-300594253212023-10-012024-09-300594253222023-10-012024-09-3005942532core:WithinOneYear2024-09-3005942532core:WithinOneYear2023-09-3005942532bus:PrivateLimitedCompanyLtd2023-10-012024-09-3005942532bus:SmallCompaniesRegimeForAccounts2023-10-012024-09-3005942532bus:FRS1022023-10-012024-09-3005942532bus:AuditExemptWithAccountantsReport2023-10-012024-09-3005942532bus:Director12023-10-012024-09-3005942532bus:CompanySecretary12023-10-012024-09-3005942532bus:FullAccounts2023-10-012024-09-30xbrli:purexbrli:sharesiso4217:GBP